1 – 3 of 3
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2013
-
Mark
Dose-densified chemoimmunotherapy followed by systemic central nervous system prophylaxis for younger high-risk diffuse large B-cell/follicular grade 3 lymphoma patients: results of a phase II Nordic Lymphoma Group study
(
- Contribution to journal › Article
- 2011
-
Mark
Nordic MCL2 Trial of 1St-Line Intensive Immunochemotherapy and Autologous Stem Cell Transplantation in Mantle Cell Lymphoma: Still Encouraging Results After Median 5½ Years Observation Time
2011) Annual Meeting of the American-Society-for-Blood-and-Marrow-Transplantation(BMT) Tandem In Biology of Blood and Marrow Transplantation 17(2). p.196-196(
- Contribution to journal › Published meeting abstract
- 2009
-
Mark
In mantle cell lymphoma (MCL) the MCL-International Prognostic Index (MIPI) is a better predictor of event-free and overall survival than International Prognostic Index (IPI) in patients receiving intensive 1st line treatment including ASCT
2009) 14th Annual Meeting of the European-Hematology-Association In Haematologica-The Hematology Journal 94. p.0971-0971(
- Contribution to journal › Published meeting abstract